HealthcareSmall capRs 3,359 crRs 7.4 cr traded a day
Close on 2026-08-21
300.00
−0.99%
52-week range33% of the way up
255.30392.10
Market cap
3,359 cr
P/E (TTM)
19.6×
industry 44×
EPS (TTM)
15.34
Revenue YoY
+2.1%
Q1 FY27
Profit YoY
-4.6%
Net margin
20.3%
-1.4pt vs a year ago
Growth trend
-19.6pt
vs last quarter’s YoY
1 month
-4.5%
Below 52w high
30.7%
RSI (14)
34
Daily swing
3.5%
average true range
Volume
1.2×
vs 20-day average
Traded
Rs 7 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−1.41%
1 month
−4.53%
3 months
−20.38%
6 months
−0.13%
1 year
−12.09%
The read
written from the numbers on this page
The evidence leans negative1 supporting, 3 against, 1 worth knowing
Supporting
priced at 20× earnings against an industry median of 44× — 56% below its peers
Against
trading 5% below its 200-day average
down 12% over twelve months
net margin has narrowed from 24.2% to 20.3% across four quarters
Worth knowing
revenue grew 2% year on year in the quarter ending 2026-06-30
What would change this read: a close back above 315, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working
Nothing in the filings stands out either way.
Needs watching1
Net margin moved from 21.8% to 20.3%.
21.8%20.3%
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
1 of 47 matched on 2026-08-21
ADVENZYMES matches 1 of the 47 scans today, across 1 different kinds of evidence.
ADVENZYMES trades at 20× trailing earnings, below its median of 25× over this window — 20% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 2% against the same quarter a year earlier
Going against it
profit dropped 5% year on year
net margin narrowed from 22.3% to 20.3%
revenue rose in 1 of the last 4 quarters
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
190
54
39
3.31
20.3%
Q4 FY26
2026-03-31 · consolidated
203
60
45
3.84
22.3%
Q3 FY26
2025-12-31 · consolidated
172
58
43
3.80
25.1%
Q2 FY26
2025-09-30 · consolidated
185
60
45
3.87
24.2%
Q1 FY26
2025-06-30 · consolidated
186
55
40
3.57
21.8%
Q4 FY25
2025-03-31 · consolidated
167
43
27
2.37
16.0%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-7.9%
Versus 200-day average-4.9%
Below 52-week high-23.5%
Above 52-week low+17.5%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)33.5
Higher closes in last 52 of 5
Six-month return−0.13%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.50%
Volume versus 20-day1.2x
Median daily turnoverRs 7.4 cr
Peers
Healthcare · 67 classified companies
ADVENZYMES trades at 19.6× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 56%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.